当前位置: X-MOL 学术Prostag. Other Lipid Mediat. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A journey of celecoxib from pain to cancer.
ProstaglandIns & Other Lipid Mediators ( IF 2.5 ) Pub Date : 2019-11-11 , DOI: 10.1016/j.prostaglandins.2019.106379
Pratiksha Saxena 1 , Pramod K Sharma 1 , Priyank Purohit 1
Affiliation  

The most enthralling and versatile class of drugs called the Non-steroidal anti-inflammatory (NSAIDs) showed its therapeutic utility in inflammation, beginning from the era of classic drug 'Aspirin'. NSAIDs and their well-established action based on inhibiting the COX-1 and COX-2 enzyme leads to blockage of prostaglandin pathway. They further categorized into first generation (non-selective inhibitor) and second generation (selective COX-2 inhibitors). Selective COX-2 inhibitors has advantage over non-selective in terms of their improved safety profile of gastro-intestinal tract. Rejuvenating and recent avenues for COXIBS (selective COX-2 inhibitors) explains its integrated role in identification of biochemical pain signaling as well as its pivotal key role in cancer chemotherapy. A key role player in this class is the Celecoxib (only FDA approved COXIB) a member of Biopharmaceutical classification system (BCS) II. Low solubility and bioavailability issues related with celecoxib lead to the development and advancement in the discovery and research of some possible formulation administered either orally, topically or via transdermal route. This review article intent to draw the bead on Celecoxib and it clearly explain extensive knowledge of its disposition profile, its dynamic role in cancer at cellular level and cardiovascular risk assessment. Some of the possible formulations approaches with celecoxib and its improvement aspects are also briefly discussed.

中文翻译:

塞来昔布从疼痛到癌症的旅程。

从经典药物“阿司匹林”时代开始,最令人着迷且用途最广泛的一类药物是非甾体抗炎药(NSAID),显示出其在炎症中的治疗作用。NSAID及其基于抑制COX-1和COX-2酶的公认作用可导致前列腺素途径的阻滞。他们进一步分为第一代(非选择性抑制剂)和第二代(选择性COX-2抑制剂)。选择性COX-2抑制剂在改善胃肠道安全性方面优于非选择性。COXIBS(选择性COX-2抑制剂)的复兴和最新途径说明了其在鉴定生化疼痛信号中的综合作用以及在癌症化疗中的关键作用。此类药物中的关键角色是Celecoxib(只有FDA批准的COXIB),它是生物制药分类系统(BCS)II的成员。与塞来昔布相关的低溶解度和生物利用度问题导致发现和研究口服,局部或经皮途径给药的某些可能制剂的发展和进步。这篇综述文章旨在在Celecoxib上画珠,并清楚地解释了其配置概况,其在细胞水平上在癌症中的动态作用以及心血管风险评估的广泛知识。还简要讨论了塞来昔布的一些可能的制剂方法及其改进方面。与塞来昔布相关的低溶解度和生物利用度问题导致发现和研究口服,局部或经皮途径给药的某些可能制剂的发展和进步。这篇综述文章旨在在Celecoxib上画珠,并清楚地解释了其配置概况,其在细胞水平上在癌症中的动态作用以及心血管风险评估的广泛知识。还简要讨论了塞来昔布的一些可能的制剂方法及其改进方面。与塞来昔布相关的低溶解度和生物利用度问题导致发现和研究口服,局部或经皮途径给药的某些可能制剂的发展和进步。这篇综述文章旨在在Celecoxib上画珠,并清楚地解释了其配置概况,其在细胞水平上在癌症中的动态作用以及心血管风险评估的广泛知识。还简要讨论了塞来昔布的一些可能的制剂方法及其改进方面。它在细胞水平和心血管风险评估中在癌症中的动态作用。还简要讨论了塞来昔布的一些可能的制剂方法及其改进方面。它在细胞水平和心血管风险评估中在癌症中的动态作用。还简要讨论了塞来昔布的一些可能的制剂方法及其改进方面。
更新日期:2019-11-01
down
wechat
bug